Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: Correlation with competitive radioimmunoassay titer

Darron Brown, J. T. Bryan, J. M. Schroeder, T. S. Robinson, Kenneth Fife, C. M. Wheeler, E. Barr, P. R. Smith, L. Chiacchierini, A. DiCello, K. U. Jansen

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Neutralization of human papillomavirus type 11 (HPV-11) has been demonstrated using serum and cervical secretions from primates vaccinated with virus-like particles (VLPs). Theoretically, neutralizing antibodies could protect women from HPV infection. The immunogenicity of a yeast-derived HPV-11 L1 VLP vaccine was tested in women. Serum specimens were evaluated for HPV-11 titer by competitive radioimmunoassay (cRIA) and for neutralization by use of the athymic mouse xenograft system. Analysis of serum from 104 subjects showed a dose response in HPV-11 cRIA titers and neutralization. Overall, 68 (82.9%) of 82 postimmunization serum specimens from VLP recipients were 100% neutralizing when used in the assay at a 1:50 dilution. Of 69 serum specimens, 63 (91.3%) with cRIA titers >200 milliMerck units per milliliter were neutralizing. Immunization with HPV VLPs elicits a vigorous serum immune response in a high percentage of women. The HPV-11 cRIA titer appears to be a surrogate marker for neutralization.

Original languageEnglish
Pages (from-to)1183-1186
Number of pages4
JournalJournal of Infectious Diseases
Volume184
Issue number9
DOIs
StatePublished - Nov 1 2001

Fingerprint

Human papillomavirus 11
Virion
Radioimmunoassay
Yeasts
Serum
Virus-Like Particle Vaccines
Neutralizing Antibodies
Heterografts
Nude Mice
Primates
Immune Sera
Immunization
Biomarkers
Infection

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles : Correlation with competitive radioimmunoassay titer. / Brown, Darron; Bryan, J. T.; Schroeder, J. M.; Robinson, T. S.; Fife, Kenneth; Wheeler, C. M.; Barr, E.; Smith, P. R.; Chiacchierini, L.; DiCello, A.; Jansen, K. U.

In: Journal of Infectious Diseases, Vol. 184, No. 9, 01.11.2001, p. 1183-1186.

Research output: Contribution to journalArticle

Brown, Darron ; Bryan, J. T. ; Schroeder, J. M. ; Robinson, T. S. ; Fife, Kenneth ; Wheeler, C. M. ; Barr, E. ; Smith, P. R. ; Chiacchierini, L. ; DiCello, A. ; Jansen, K. U. / Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles : Correlation with competitive radioimmunoassay titer. In: Journal of Infectious Diseases. 2001 ; Vol. 184, No. 9. pp. 1183-1186.
@article{da38e7764df24602a48905e27690441e,
title = "Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: Correlation with competitive radioimmunoassay titer",
abstract = "Neutralization of human papillomavirus type 11 (HPV-11) has been demonstrated using serum and cervical secretions from primates vaccinated with virus-like particles (VLPs). Theoretically, neutralizing antibodies could protect women from HPV infection. The immunogenicity of a yeast-derived HPV-11 L1 VLP vaccine was tested in women. Serum specimens were evaluated for HPV-11 titer by competitive radioimmunoassay (cRIA) and for neutralization by use of the athymic mouse xenograft system. Analysis of serum from 104 subjects showed a dose response in HPV-11 cRIA titers and neutralization. Overall, 68 (82.9{\%}) of 82 postimmunization serum specimens from VLP recipients were 100{\%} neutralizing when used in the assay at a 1:50 dilution. Of 69 serum specimens, 63 (91.3{\%}) with cRIA titers >200 milliMerck units per milliliter were neutralizing. Immunization with HPV VLPs elicits a vigorous serum immune response in a high percentage of women. The HPV-11 cRIA titer appears to be a surrogate marker for neutralization.",
author = "Darron Brown and Bryan, {J. T.} and Schroeder, {J. M.} and Robinson, {T. S.} and Kenneth Fife and Wheeler, {C. M.} and E. Barr and Smith, {P. R.} and L. Chiacchierini and A. DiCello and Jansen, {K. U.}",
year = "2001",
month = "11",
day = "1",
doi = "10.1086/323645",
language = "English",
volume = "184",
pages = "1183--1186",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles

T2 - Correlation with competitive radioimmunoassay titer

AU - Brown, Darron

AU - Bryan, J. T.

AU - Schroeder, J. M.

AU - Robinson, T. S.

AU - Fife, Kenneth

AU - Wheeler, C. M.

AU - Barr, E.

AU - Smith, P. R.

AU - Chiacchierini, L.

AU - DiCello, A.

AU - Jansen, K. U.

PY - 2001/11/1

Y1 - 2001/11/1

N2 - Neutralization of human papillomavirus type 11 (HPV-11) has been demonstrated using serum and cervical secretions from primates vaccinated with virus-like particles (VLPs). Theoretically, neutralizing antibodies could protect women from HPV infection. The immunogenicity of a yeast-derived HPV-11 L1 VLP vaccine was tested in women. Serum specimens were evaluated for HPV-11 titer by competitive radioimmunoassay (cRIA) and for neutralization by use of the athymic mouse xenograft system. Analysis of serum from 104 subjects showed a dose response in HPV-11 cRIA titers and neutralization. Overall, 68 (82.9%) of 82 postimmunization serum specimens from VLP recipients were 100% neutralizing when used in the assay at a 1:50 dilution. Of 69 serum specimens, 63 (91.3%) with cRIA titers >200 milliMerck units per milliliter were neutralizing. Immunization with HPV VLPs elicits a vigorous serum immune response in a high percentage of women. The HPV-11 cRIA titer appears to be a surrogate marker for neutralization.

AB - Neutralization of human papillomavirus type 11 (HPV-11) has been demonstrated using serum and cervical secretions from primates vaccinated with virus-like particles (VLPs). Theoretically, neutralizing antibodies could protect women from HPV infection. The immunogenicity of a yeast-derived HPV-11 L1 VLP vaccine was tested in women. Serum specimens were evaluated for HPV-11 titer by competitive radioimmunoassay (cRIA) and for neutralization by use of the athymic mouse xenograft system. Analysis of serum from 104 subjects showed a dose response in HPV-11 cRIA titers and neutralization. Overall, 68 (82.9%) of 82 postimmunization serum specimens from VLP recipients were 100% neutralizing when used in the assay at a 1:50 dilution. Of 69 serum specimens, 63 (91.3%) with cRIA titers >200 milliMerck units per milliliter were neutralizing. Immunization with HPV VLPs elicits a vigorous serum immune response in a high percentage of women. The HPV-11 cRIA titer appears to be a surrogate marker for neutralization.

UR - http://www.scopus.com/inward/record.url?scp=0035500950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035500950&partnerID=8YFLogxK

U2 - 10.1086/323645

DO - 10.1086/323645

M3 - Article

C2 - 11598842

AN - SCOPUS:0035500950

VL - 184

SP - 1183

EP - 1186

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 9

ER -